Big Pharma biopharma buyouts boost M&A activity in Q4

Related tags Pharmaceutical industry

Big Pharma biopharma buyouts boost M&A activity in Q4
Big Pharma takeovers of small biopharmaceutical companies to refill pipelines increased the volume and value of dealmaking in Q4 according to a new report by PwC.

According to the report pharma industry M&A activity increased 24% in the three months to December 31 and the total value of the deals grew 102.8% to over $37bn (€27bn), which acquisitions in the biopharmaceutical space providing much of the impetus.

MedImmune’s acquisition of Aplimmune​ and Amgen’s takeover of Onyx​ were among the major biopharma sector deals deals the PriceWaterhouscoopers (PwC) team said had driven the increase in value.

Large pharmaceutical companies, which historically have been frequent acquirers, focused on rebuilding their product pipelines through acquisitions of relatively smaller biopharmaceutical players​.”

Similarly, they cited Salix Pharmaceutical’s takeover of gastroenterology-focused biopharmaceutical firm Santarus for $2.6bn, Grifols $1.7bn purchase of Novartis’ blood diagnostics business and Endo Health Solutions $1.6bn acquisition of Paladin as important.

Related topics Markets & Regulations Facilities

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers